Details of the Drug Combinations

General Information of This Drug (ID: DMP8HW1)

Drug Name

LY2157299 DMP8HW1

Synonyms

Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Phase 2/3	[1]
Non-small-cell lung cancer	2C25.Y	Phase 2/3	[2]
Hepatocellular carcinoma	2C12.02	Phase 2	[2]
Glioma	2A00.0	Phase 1/2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
Pancreatic cancer	2C10	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
LY2157299 + Methotrexate	DCLOBLC	Methotrexate	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
LY2157299 + Mebendazole	DC37GAI	Mebendazole	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
------------------------------------------------------------------------------------

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gemcitabine + LY2157299	DCTUMXU	Gemcitabine	Neoplasms	[5]
Lomustine + LY2157299	DCEAF6A	Lomustine	Glioblastoma	[6]
Enzalutamide + LY2157299	DCCOML3	Enzalutamide	Prostate Cancer	[7]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7797).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT01373164) A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
6	ClinicalTrials.gov (NCT01582269) A Study in Recurrent Glioblastoma (GB)
7	ClinicalTrials.gov (NCT02452008) Study of TGF- Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer